Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Short term Debt (2023 - 2024)

Historic Short term Debt for TScan Therapeutics (TCRX) over the last 2 years, with Q2 2024 value amounting to $10.3 million.

  • TScan Therapeutics' Short term Debt changed N/A to $10.3 million in Q2 2024 from the same period last year, while for Jun 2024 it was $10.3 million, marking a year-over-year change of. This contributed to the annual value of $3.3 million for FY2023, which is N/A changed from last year.
  • TScan Therapeutics' Short term Debt amounted to $10.3 million in Q2 2024.
  • TScan Therapeutics' 5-year Short term Debt high stood at $10.3 million for Q2 2024, and its period low was $1.1 million during Q3 2023.